Table 2—

Statistical analysis of meal test–derived parameters, FPG, A1C, and body weight in the intention-to-treat population

nBaselineAdjusted mean changeBetween-group differenceP
GLP-1 AUC0–2 h (pmol · l−1 · h−1)
    Vildagliptin 50 mg q.d.735.7 ± 1.28.5 ± 0.78.8 ± 1.0<0.001
    Placebo746.0 ± 1.1−0.3 ± 0.7
GLP-1 ΔAUC0–2 h (pmol · l−1 · h−1)
    Vildagliptin 50 mg q.d.731.1 ± 0.25.8 ± 0.86.0 ± 1.2<0.001
    Placebo740.9 ± 0.3−0.2 ± 0.8
GIP AUC0–2 h (pmol · l−1 · h−1)
    Vildagliptin 50 mg q.d.4741.7 ± 2.353.2 ± 4.351.3 ± 5.4<0.001
    Placebo5050.9 ± 3.21.8 ± 4.5
GIP ΔAUC0–2 h (pmol · l−1 · h−1)
    Vildagliptin 50 mg q.d.4725.1 ± 2.141.3 ± 4.346.8 ± 5.4<0.001
    Placebo5033.8 ± 3.0−5.5 ± 4.5
Glucagon AUC0–2 h (pmol · l−1 · h−1)
    Vildagliptin 50 mg q.d.7943.1 ± 1.2−1.9 ± 0.8-3.3 ± 1.20.007
    Placebo7643.7 ± 1.41.4 ± 0.8
Glucagon ΔAUC0–2 h (pmol · l−1 · h−1)
    Vildagliptin 50 mg q.d.791.7 ± 0.7−2.8 ± 0.8-3.0 ± 1.00.003
    Placebo762.2 ± 0.70.2 ± 0.7
Insulin AUC0–2 h (pmol · l−1 · h−1)
    Vildagliptin 50 mg q.d.74653 ± 43−29.4 ± 26.236.8 ± 37.40.327
    Placebo73750 ± 52−66.1 ± 26.8
Insulin ΔAUC0–2 h (pmol · l−1 · h−1)
    Vildagliptin 50 mg q.d.74524 ± 37−37.6 ± 25.020.8 ± 35.70.561
    Placebo73619 ± 45-58.4 ± 25.6
Glucose AUC0–2 h (mmol · l−1 · h−1)
    Vildagliptin 50 mg q.d.8315.8 ± 0.3−0.9 ± 0.2-1.0 ± 0.3<0.001
    Placebo8215.9 ± 0.30.1 ± 0.2
Glucose ΔAUC0–2 h (mmol · l−1 · h−1)
    Vildagliptin 50 mg q.d.833.2 ± 0.2−0.7 ± 0.2-1.0 ± 0.3<0.001
    Placebo823.5 ± 0.20.3 ± 0.2
Peak prandial glucose excursion (mmol/l)
    Vildagliptin 50 mg q.d.853.0 ± 0.1−0.6 ± 0.1−0.6 ± 0.2<0.001
    Placebo853.3 ± 0.10.1 + 0.1
2-h postprandial plasma glucose level (mmol/l)
    Vildagliptin 50 mg q.d.846.8 ± 0.2−0.2 ± 0.1−0.3 ± 0.20.067
    Placebo826.8 ± 0.10.1 ± 0.1
Insulin secretion relative to glucose (ISR AUC0–2 h/glucose AUC0–2 h [pmol · min−1 · m−2 · mmol · l−1])
    Vildagliptin 50 mg q.d.7658.6 ± 2.04.7 ± 1.46.4 ± 2.00.002
    Placebo7660.4 ± 2.2-1.7 ± 1.5
FPG (mmol/l)
    Vildagliptin 50 mg q.d.896.18 ± 0.08−0.03 ± 0.06−0.04 ± 0.080.660
    Placebo896.10 ± 0.080.00 ± 0.06
A1C (%)
    Vildagliptin 50 mg q.d.855.93 ± 0.06−0.13 ± 0.03−0.15 ± 0.04<0.001
    Placebo785.89 ± 0.050.02 ± 0.03
Body weight (kg)
    Vildagliptin 50 mg q.d.8987.1 ± 1.5−0.6 ± 0.2−0.5 ± 0.30.125
    Placebo8986.9 ± 1.8−00.1 ± 0.2
  • Data are means ± SEM.